Since the concept of TfR binding to pass the BBB to treat MPS2 and neuronal ceroid lipofuscinosis (NCL) has been validated in humans56,57, we now extend these findings for neuronopathic GD. Here, TFRC is linked to neuronal ceroid lipofuscinosis.